PRaG regimens (PD-1 inhibitor combined with radiotherapy and GM-CSF with or not IL-2) rechallenge for patients with acquiring resistance to PD-1/PD-L1 inhibitors in refractory advanced solid tumors.

Authors

null

Meiling Xu

The Second Affiliated Hospital of Soochow University, Suzhou, China

Meiling Xu , Pengfei Xing , Yuehong Kong , Chenyang Zhang , Xiangrong Zhao , Junjun Zhang , Liyuan Zhang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

PD1/PD-L1 Inhibitor Combinations

Clinical Trial Registration Number

ChiCTR1900020175 and NCT04892498

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 2601)

DOI

10.1200/JCO.2022.40.16_suppl.2601

Abstract #

2601

Poster Bd #

256

Abstract Disclosures